Picture of Ashland logo

ASH — Ashland News Story

0.000.00%
us flag iconLast trade - 00:00
Basic MaterialsBalancedLarge CapNeutral

Ashland Q4 adjusted profit misses estimates; forecasts higher 2027 sales

Ashland Q4 adjusted profit misses estimates; forecasts higher 2027 sales


Overview

  • U.S. specialty ingredients maker's fiscal Q4 revenue rose 4% but slightly missed analyst expectations

  • Adjusted EPS for Q4 missed analyst expectations despite rising to $1.12 from $1.08 a year earlier

  • Company posted a net loss of $16 mln, versus net income a year earlier


Outlook

  • Ashland sees fiscal 2027 sales of $1.905-$1.975 bln

  • Company expects fiscal 2027 adjusted EBITDA of $405-$435 mln

  • Ashland expects resilient demand in Life Sciences and Personal Care for fiscal 2027


Result Drivers

  • HIGHER SALES VOLUMES - Co said Q4 sales volumes increased, driven by Life Sciences and Personal Care growth

  • PRICE INCREASES - Co said pricing actions offset higher raw material costs in Q4

  • SPECIALTY ADDITIVES PRESSURE - Co said lower Hopewell productivity and unfavorable absorption reduced Specialty Additives earnings


Company press release: ID:nGNX7yHWJn


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Slight Miss*

$498 mln

$501.81 mln (8 Analysts)

Q4 Loss Per Share

$0.35

Q4 Net Loss

$16 mln

Q4 Adjusted EPS

Miss

$1.12

$1.28 (10 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the diversified chemicals peer group is "buy"

  • Wall Street's median 12-month price target for Ashland Inc. is $80.00, about 9.6% above its November 3 closing price of $73.02

  • The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 17 three months ago


Reuters Recommended Reads

  • Nov 3 - DuPont raises annual profit forecasts, sees upbeat Q4 on healthcare, aerospace strength

  • Nov 2 - Celanese Q3 sales rise 6%

  • Nov 3 - Flavors and fragrances maker IFF's Q3 sales beat; low end of 2026 outlook raised


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Ashland

See all news